Journal article

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants - A randomized controlled trial

Matthew D Snape, Kirsten P Perrett, Karen J Ford, Tessa M John, David Pace, Ly-Mee Yu, Joanne M Langley, Shelley McNeil, Peter M Dull, Francesca Ceddia, Alessandra Anemona, Scott A Halperin, Simon Dobson, Andrew J Pollard

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | AMER MEDICAL ASSOC | Published : 2008

Abstract

CONTEXT: Immunization with a meningococcal tetravalent (serogroup ACWY) glycoconjugate vaccine is recommended for all US adolescents. However, the currently licensed vaccine is poorly immunogenic in infancy, when the highest rates of disease are observed. OBJECTIVE: To determine the immunogenicity of a novel tetravalent CRM(197)-conjugated meningococcal vaccine (MenACWY) in infants. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, controlled study of 225 UK and 196 Canadian 2-month-olds from August 2004 to September 2006. INTERVENTION: UK infants received a primary course of MenACWY (at 2, 3, and 4 months or 2 and 4 months) or Neisseria meningitidis serogroup C monovalent meningoco..

View full abstract